177017-68-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-(+)-6-METHOXY 2-AMINOTETRALIN is used as a pharmacological agent for its potential therapeutic applications in treating neurological disorders. Its role as a potent dopamine agonist makes it a candidate for the treatment of Parkinson's disease, where dopamine levels are depleted, leading to motor impairments.
Used in Neurological Research:
In the field of neurological research, (R)-(+)-6-METHOXY 2-AMINOTETRALIN is utilized as a research tool to study the effects of dopamine agonism on the brain. Its potential to modulate neurotransmitter systems could provide insights into the development of treatments for various neurological conditions.
Used in Neuropsychiatric Applications:
(R)-(+)-6-METHOXY 2-AMINOTETRALIN is also considered for its potential use in neuropsychiatric applications, where modulation of neurotransmitter systems could lead to therapeutic benefits for patients suffering from neuropsychiatric disorders. Its precise mechanisms of action and effects on neurotransmission are areas of ongoing investigation.

InChI:InChI=1/C11H15NO/c1-13-11-5-3-8-6-10(12)4-2-9(8)7-11/h3,5,7,10H,2,4,6,12H2,1H3/t10-/m1/s1

Upstream product

• 1447-87-6 2-hydroxy-6-methoxy-1,2,3,4-tetrahydronaphthalene 
• 2472-22-2 6-methoxy-2-tetralone 
• 281199-10-8 2-((R)-6-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-isoindole-1,3-dione 
• 5486-55-5 2,6-dimethoxylnaphthalene 
• 581-43-1 2.6-dihydroxynaphthalene 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 
• 744174-28-5 N-benzyl-6-methoxytetralin-2-amine 
• 81861-29-2 6-Methoxy-3,4-dihydro-1H-naphthalen-2-one O-methyl-oxime 
• 37563-97-6 6-methoxy-3,4-dihydro-[1,2]-naphthoquinone-2-oxime 
• 52178-91-3 7-methoxy-1,2-dihydronaphthalene 
• 623-26-7 terephthalonitrile 
• 2398-37-0 3-methoxyphenyl bromide 
• 104-92-7 1-bromo-4-methoxy-benzene 

Downstream Products

• 4003-88-7 2-amino-6-methoxy-1,2,3,4-tetrahydronaphthalene hydrochloride 
• 70312-01-5 2-amino-1,2,3,4-tetrahydro-6-hydroxynaphthalene 

Relevant academic research and scientific papers

Artificial multi-enzyme networks for the asymmetric amination of sec-alcohols

Various artificial network designs that involve biocatalysts were tested for the asymmetric amination of sec-alcohols to the corresponding α-chiral primary amines. The artificial systems tested involved three to five redox enzymes and were exemplary of a range of different sec-alcohol substrates. Alcohols were oxidised to the corresponding ketone by an alcohol dehydrogenase. The ketones were subsequently aminated by employing a ω-transaminase. Of special interest were redox-neutral designs in which the hydride abstracted in the oxidation step was reused in the amination step of the cascade. Under optimised conditions up to 91 % conversion of an alcohol to the amine was achieved. Trickle-down effect: The asymmetric amination of sec-alcohols to the corresponding α-chiral primary amines was performed with a biocatalytic cascade whereby the various steps were interconnected through the cofactors/cosubstrates. In a redox-neutral cascade and under optimised conditions, up to 91 % conversion of an alcohol to the amine was achieved. Copyright

A novel asymmetric route to 2-amino-1,2,3,4-tetrahydronaphthalenes

A novel asymmetric route to 2-amino-1,2,3,4-tetrahydronaphthalenes has been demonstrated starting from phthalimidovinylglycinol (PVG). Functionalisation of PVG via Heck reaction, olefin hydrogenation and cyclisation provides the title products. (C) 2000 Elsevier Science Ltd.

INDOLE AHR INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

Synthesis and cycloxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalen-methylsulfonamido compounds

We synthesized a series of new naphthalene derivatives: naproxen- and 6-methoxy naphthalene acetic acid-like 1-5. In these compounds the carboxylic function, typical of the classical NSAIDs, was replaced by a methylsulfonamido (1, 2 and 6a-c) or methylsulfonyl (3-5) group present in some selective COX-2 inhibitors. We also synthesized compounds 7 and 8 in which the naphthalene portion was substituted by tetrahydronaphthalene ring. Some of the new compounds were assayed for their enzymatic inhibitory activity towards cycloxygenase enzymes. Compounds 4 and 6b, at a concentration of 10 μM exhibit percentage inhibition values of 65%, 50% and 29%, 87% towards COX-2 and COX-1, respectively. The substitution of carboxylic group with a mehylsulfonamido or a methylsulfonyl groups does not allow to direct the selectivity versus to cycloxygenase enzymes.

Asymmetric amination of tetralone and chromanone derivatives employing ω-transaminases

Various (S)-selective and (R)-selective ω-transaminases were investigated for the amination of 1- and 2-tetralone and derivatives as well as of 3- and 4-chromanone. All ketones tested were aminated to give the corresponding enantiopure amines (ee > 99%) employing at least one of the enzymes investigated. In most of the cases the (S)- as well as the (R)-enantiomer was obtained in optically pure form. The amination of 3-chromanone was performed on a 100 mg scale leading to optically pure (R)-3-aminochromane (ee > 99%) with complete conversion and 78% isolated yield.

Synthesis and antifungal activities of novel 2-aminotetralin derivatives

Novel 2-aminotetralin derivatives were synthesized as antifungal agents. The 2-aminotetralin scaffold was chemically designed to mimic the tetrahydroisoquinoline ring of the lead molecule described before. Their antifungal activities were evaluated in vitro by measuring the minimal inhibitory concentrations (MICs). Compounds 10a, 12a, 12c, 13b, and 13d are more potent than fluconazole against seven testing human fungal pathogens. Compound 10b exhibits much higher antifungal activities against all of the four fluconazole-resistant clinic Candida albicans strains than the control drugs including amphotericin B, terbinafine, ketoconazole, and itraconazole. The mode of action of some compounds to the potential receptor lanosterol 14α-demethylase (CYP51) was investigated by molecular docking. The studies presented here provide a new structural type for the development of novel antifungal compounds. Furthermore, 10b was evaluated in vivo by a rat vaginal candidiasis model, and it was found that 10b significantly decreases the number of fungal colony counts.

SUBSTITUTED TETRALINS AND INDANES AND THEIR USE

This invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, diabetes.

SUBSTITUTED TETRALINS AND INDANES

The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, dyslipidemia.

DPP IV inhibitors

The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

Substituted pyridines/pyrimidines, their preparation and their use as pesticides

The present invention relates to novel substituted pyridines/pyrimidines of the formula I where A is CH or N; X is NH, O or S(O)qwhere q is 0, 1 or 2; Y1, Y2and Y3independently of one another are a group of the